Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine
Jan Gerstoft, Jens Lundgren(Centre of Excellence for Health, Immunity and Infections), Niels Obel(University of Copenhagen), Ole Kirk(University of Copenhagen), Terese L. Katzenstein, Court Pedersen(Office of Infectious Diseases), Henrik Nielsen(Aalborg University Hospital)
Cited by 80
Related Papers
Industrial enzyme applications
|Current Opinion in Biotechnology|2002|1.5k
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
|The Lancet|2003|1.2k
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
|The Journal of Infectious Diseases|2011|1.1k